Retrospective Survey of Hyperkalemia in Hemodialysis
Visualize-HD
A Multicenter Retrospective Survey of Hyperkalemia Clinical Burden on Hemodialysis Facility-level in China
1 other identifier
observational
300
1 country
1
Brief Summary
This study aim to describe hyperkalemia clinical burden and investigate the risk factors associated with the burden on HD facility level.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 17, 2021
CompletedFirst Posted
Study publicly available on registry
August 25, 2021
CompletedStudy Start
First participant enrolled
September 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedAugust 25, 2021
August 1, 2021
11 months
August 17, 2021
August 24, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
To investigate the risk factors associated with hyperkalemia clinical burden on HD facility level
Examine the association of risk factors at current status to hyperkalemia prevalence on HD facility level
3 years
Secondary Outcomes (3)
To describe hyperkalemia clinical burden on HD facility level
3 years
To describe sK management pattern on HD facility level
3 years
To investigate the risk factors associated with crude mortality on HD facility level
3 years
Other Outcomes (1)
To investigate the risk factors associated with sK > 6.0 mmol/L and sK > 6.5 mmol/L on HD facility level
3 years
Eligibility Criteria
HD centers in China
You may qualify if:
- For HD centers:
- ≥ 100 patients under MHD within 3 years prior the study initiation
- Willing to participate in the study
- Have routine blood collection after LIDI
- Have death records
- For HD patients:
- On chronic HD for ≥ 3 months
You may not qualify if:
- Blood test on other days than those after LIDI
- Unable to provide detailed data required by study protocol
- Being unable to comply with study-specified procedure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking University People's Hospitallead
- AstraZenecacollaborator
Study Sites (1)
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Related Publications (2)
Xinju Z, Changying X, Hong L, Guisen L, Ping Z, Caili W, Zuying X, Gang X, Rong W, Rongshan L, Aili J, Hongli J, Jianxin W, Xiaoling W, Jing Y, Li Y, Pei W, Rui Z, Yunhua L, Huimin L, Jinsheng X, Menghua C, Yinhui L, Qinkai C, Zhongfei Y, Yan Z, Hong L, Wenbo H, Chen L, Zhaohui N, Lingling G, Li Z. Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study. Sci Rep. 2025 Jul 1;15(1):22405. doi: 10.1038/s41598-025-92609-1.
PMID: 40596462DERIVEDZhao X, Zuo L. Multicentre, observational, retrospective cohort of hyperkalaemia burden at haemodialysis facility-level in China: the Visualize-HD study protocol. BMJ Open. 2023 Sep 21;13(9):e066394. doi: 10.1136/bmjopen-2022-066394.
PMID: 37734899DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Li Zuo
Peking University People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Nephrology Department
Study Record Dates
First Submitted
August 17, 2021
First Posted
August 25, 2021
Study Start
September 1, 2021
Primary Completion
August 1, 2022
Study Completion
December 1, 2022
Last Updated
August 25, 2021
Record last verified: 2021-08